Irina Rebin

Irina is member of the Practice Area Patents Technology & Life Sciences and the Life Sciences & Healthcare Industry Group. Her practice includes advising pharmaceutical, medical device, and biotechnology companies and investors on all regulatory matters throughout the entire life cycle of medicinal products, medical devices, and IVDs: from preclinical research and clinical trials, manufacturing, and market access to distribution (including post-market surveillance).

She also provides legal advice on genetic engineering, food (including food supplements), and cosmetics. Irina complements this practice focus by drafting and negotiating corresponding industry-specific agreements (including research and development agreements, license agreements, clinical trial agreements, contract/manufacturing and distribution agreements (including quality agreements)) and by advising on (cross-border) transactions in the healthcare sector.

CV

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

Career

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

Education

2019 Second state examination, Munich

2014 – 2017 Doctoral studies at Ludwig Maximilians University Munich

2014 - 2015 Doctoral studies at Georg August University Göttingen

Publications

§§ 40-42e AMG in: Rehmann, AMG, 6. Aufl. [in Bearb./vor. Anfang 2026] § 15 Entwicklung des Arzneimittelprüfrechts

§ 16 Grundlagen klinischer Arzneimittelprüfungen

§ 17 Zentrale Voraussetzungen klinischer Prüfungen im Überblick in: Spickhoff/Handorn: Handbuch Medizinisches Forschungsrecht, C. H. Beck, München, 2023

§ 2 ProdHaftG im Beck-Online-Großkommentar (seit 2015)

Additional languages

Awards

JUVE Awards 2023

Featured

Irina's news & insights

View Irina's insights

Click here to find out more

Medical devices

Update: AI-Enabled Medical Devices and IVDs Confirmed as “High-Risk”

2 July 2026

by Irina Rebin

International Life Sciences Newsletter - Life Sciences Legal Lens Vol. 2

Medical Cannabis Platforms Breach Advertising Ban

Case law – German Federal Court of Justice (Bundesgerichtshof) – Online platforms brokering medical cannabis treatments breach the prohibition of public advertising under the German Healthcare Advertising Act

2 July 2026

Briefing

by Irina Rebin

7 of 9 Insights

Click here to find out more

International Life Sciences Newsletter - Life Sciences Legal Lens Vol. 2

CJEU on distributor's verification obligations under MDR

Medical device (and IVD) distributors. CJEU confirms that distributors need not repeat the manufacturer’s classification or conformity assessment, but must perform a “consistency check” for obvious inconsistencies.

1 July 2026

Briefing

by Irina Rebin

1 of 9 Insights

Click here to find out more

Irina Rebin

JUVE Awards 2023

Expertise

Services and Groups

Sectors